SPIMACO Pharmaceutical Company announced today on tadawul signing 7 years renewable agreement with Turkey-based Abdi Ibrahim Company (GSK) to market and distribute 5 products the Turkish market.
These products are expected to be offered in the Turkish market during the first half of 2014 and expected to generate SAR 112m sales revenues per annum to SPIMACO.
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}